+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Artificial T-Cell Receptors Market Research and Forecast, 2019-2025

  • PDF Icon


  • February 2019
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 4753703
Global Artificial T-Cell Receptors Market Size, Share & Trends Analysis Report by Tumor Type (Cancer, and Immunological Disorders), by Therapy (Autologous, and Allogenic), By End-User (Research Institutes, Hospitals, and Biotech Companies), And Segment Forecasts, 2019 - 2025.

Artificial T-Cell Receptors often called as Chimeric Antigen Receptor (CAR) or Chimeric T-Cell Receptor are bound to surface of T-cells and serve the purpose of alerting immune systems about the impending virus attack. Synthesized T-cell receptors can control the affinity of T-cell receptors that surge its adoption in various application such as drug discovery. Personalized medicines are more effective and tend to have less adverse effects as these medicines contain some biological content. This rises their demand for the treatment of chronic disorders such as cancer. Furthermore, increasing incidences of immunological disorders such as chronic granulomatous disease and rising prevalence of chronic disorders such as cancer, and cardiovascular diseases are adding meaning growth to the market.

Furthermore, the market has been segmented, on the basis of regions, into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is anticipated to dominate the market and is expected to do so over the forecast period. Major factors augmenting the growth of artificial T-cell receptors market in North America are increasing number of cancer patients, and significant number of organizations involved in cell-based research. Moreover, the region homes several biotechnology companies that make use of artificial T-cell receptors for the development of new drugs and therapy, which fuels the market growth in the region. In addition, Asia-Pacific is estimated to exhibit the highest growth rate than any other regions across the globe. The growth of the Asia-Pacific region is attributed to rapidly aging population along with the growing number of cancer patients and high penetration of new technologies in the region.

Major market players operating in the global artificial T-cell receptors market include Pfizer, Inc., Thermo Fisher Scientific, Inc., Novartis AG, Eli Lilly & Co., and Lonza Group Ltd. These companies adopt various strategies such as geographical expansion, merger & acquisition, partnerships & collaborations, finding a new market or innovations in their core competency in order to stay competitive in the market.

Research Methodology

The market study of the global artificial T-cell receptors market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the publisher's.

Secondary sources include:
  • Financial reports of companies involved in the market

  • Authentic Public Databases such as the OECD, WHO, American Cancer Society, World Cancer Research Fund and others

  • Whitepapers, research-papers and news blogs

  • Company websites and their product catalogue.

The report is intended for research organizations, biotechnology companies, investment companies, government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation:

Global artificial T-cell receptors market is segmented on the basis of regional outlook and following segments:
1. Global Artificial T-Cell Receptors Market Research and Analysis by Disease
2. Global Artificial T-Cell Receptors Market Research and Analysis by Therapy
3. Global Artificial T-Cell Receptors Market Research and Analysis by End-User
4. Global Artificial T-Cell Receptors Market Research and Analysis by Geography

The Report Covers:
  • Comprehensive research methodology of the global artificial T-cell receptors market.

  • This report also includes a detailed and extensive market overview with key analyst insights.

  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

  • Analysis of regional regulations and other government policies impacting the global artificial T-cell receptors market.

  • Insights about market determinants which are stimulating the global artificial T-cell receptors market.

  • Detailed and extensive market segments with regional distribution of forecast revenues.

  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Eli Lilly & Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Thermo Fisher Scientific, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Lonza Group Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Novartis AG Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Artificial T-Cell Receptors Market by Disease
5.1.1. Cancer Acute Lymphoblastic Leukemia (ALL) Diffuse Large B-Cell Lymphoma Other Cancer Types
5.1.2. Immunological Disorders
5.2. Global Artificial T-Cell Receptors Market by Therapy
5.2.1. Autologous
5.2.2. Allogenic
5.3. Global Artificial T-Cell Receptors Market by End-User
5.3.1. Research Institutes
5.3.2. Hospitals
5.3.3. Biotech Companies
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Adaptive Biotechnologies Corp.
7.2. Athenex, Inc.
7.3. Blubird Bio, Inc.
7.4. Cabaletta Bio, Inc.
7.5. Celgene Corp.
7.6. Cell Medica Ltd.
7.7. Eli Lilly & Co.
7.8. Juno Therapeutics, Inc.
7.9. Kite Pharma, Inc.
7.10. Lonza Group Ltd.
7.11. Medicomp Systems, Inc.
7.12. Medigene AG
7.13. NexImmune Inc.
7.14. Novartis AG
7.15. Oxford BioMedica PLC
7.16. Pfizer, Inc.
7.17. Precision Biosciences, Inc.
7.18. STEMCELL Technologies Inc.
7.19. TCR² Therapeutics Inc.
7.20. Thermo Fisher Scientific, Inc.
7.21. Unum Therapeutics, Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Adaptive Biotechnologies Corp.

  • Athenex, Inc.

  • Blubird Bio, Inc.

  • Cabaletta Bio, Inc.

  • Celgene Corp.

  • Cell Medica Ltd.

  • Eli Lilly & Co.

  • Juno Therapeutics, Inc.

  • Kite Pharma, Inc.

  • Lonza Group Ltd.

  • Medicomp Systems, Inc.

  • Medigene AG

  • NexImmune Inc.

  • Novartis AG

  • Oxford BioMedica PLC

  • Pfizer, Inc.

  • Precision Biosciences, Inc.

  • STEMCELL Technologies Inc.

  • TCR² Therapeutics Inc.

  • Thermo Fisher Scientific, Inc.

  • Unum Therapeutics, Inc.